{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:18Z","timestamp":1792607958013,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ahj.2018.12.007","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T11:37:44Z","timestamp":1547120264000},"page":"18-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"special_numbering":"C","title":["Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants"],"prefix":"10.1016","volume":"210","author":[{"given":"Henock G","family":"Yebyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne E","family":"Aschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo A","family":"Puhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2018.12.007_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol\u202f: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.12.007_bb0010","first-page":"1","article-title":"Statins for primary prevention of cardiovascular Patients need better tools to navigate divergent recommendations","volume":"355","author":"Otto","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.12.007_bb0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2018.12.007_bb0025","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults","volume":"316","author":"US Preventive Services Tast Force","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.12.007_bb0030","first-page":"246","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"67","author":"Stone","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.ahj.2018.12.007_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the Eu","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.12.007_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"ACC\/AHA Prevention Guideline 2013 ACC \/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.12.007_bb0045","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S1470-2045(16)00152-2","article-title":"Under-reporting of harm in clinical trials","volume":"17","author":"Seruga","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0050","first-page":"i4992","article-title":"Statins: We need an independent review","volume":"354","author":"Fiona","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0055","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1001\/jama.2016.15085","article-title":"Statins for primary prevention: The debate is intense, but the data are weak","volume":"316","author":"Redberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.12.007_bb0060","first-page":"1491","article-title":"Healthy Men Should Not Take Statins","volume":"307","author":"Redberg","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.12.007_bb0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: A common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0070","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.12.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034785","article-title":"Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual Outcomes","volume":"7","author":"Pogue","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2018.12.007_bb0080","first-page":"1","article-title":"Dangers of non-specific composite outcome measures the effect of treatment","volume":"6782","author":"Prieto-merino","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0085","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.12.007_bb0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0100","series-title":"Introduction to Meta-Analysis","first-page":"1","author":"Borenstein","year":"2008"},{"key":"10.1016\/j.ahj.2018.12.007_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/eb-2013-101340","article-title":"Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk","volume":"19","author":"Newcombe","year":"2014","journal-title":"Evid Based Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ahj.2018.12.007_bb0115","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/sim.4172","article-title":"Multivariate meta-analysis: potential and promise","volume":"30","author":"Jackson","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"Stata J"},{"key":"10.1016\/j.ahj.2018.12.007_bb0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jrsm.1049","article-title":"Accounting for correlation in network meta-analysis with multi-arm trials","volume":"3","author":"Franchini","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ahj.2018.12.007_bb0130","first-page":"1","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess (Rockv)"},{"key":"10.1016\/j.ahj.2018.12.007_bb0135","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.12.007_bb0140","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0145","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0150","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ahj.2018.12.007_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0165","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0170","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0175","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0180","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"Series","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0185","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0190","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/sim.1752","article-title":"Controlling the risk of spurious findings from meta-regression","volume":"23","author":"Higgins","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/qjmed\/hct041","article-title":"Comparative effects of statins on major cerebrovascular placebo-controlled and active-comparator trials","volume":"106","author":"Naci","year":"2013","journal-title":"Q J Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0205","first-page":"1077","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"29","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.12.007_bb0210","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.12.007_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2018.12.007_bb0220","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.12.007_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at clinical trials.gov and published in corresponding journal articles","volume":"13","author":"Tang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-12-51","article-title":"Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis","volume":"12","author":"Macedo","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0235","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2018.12.007_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12872-018-0838-9","article-title":"Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts","volume":"18","author":"Yebyo","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2018.12.007_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-1279","article-title":"Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: A modeling study","volume":"170","author":"Yebyo","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0250","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.12.007_bb0255","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:01:59Z","timestamp":1757570519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318303466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":51,"alternative-id":["S0002870318303466"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.12.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}